Takeda entered into an exclusive licensing agreement with Hutchmed Limited to develop its colorectal cancer candidate, fruquintinib, beyond mainland China, Hong Kong and Macau.
https://www.pharmalive.com/wp-content/uploads/2022/01/Takeda-Augments-IO-Portfolio-with-Third-Build-to-Buy-Acquisition-in-a-Year-BioSpace-1-10-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-01-23 09:43:522023-01-23 09:43:52Takeda puts up $1B-Plus for Hutchmed’s colorectal cancer drug
